Prostate Cancer

Rapid advances propel prostate biopsy forward

September 28, 2020

Advanced imaging and improvements in biopsy techniques usher in a new paradigm for screening and diagnosis.

Ipatasertib/abiraterone regimen delays progression in mCRPC with PTEN loss

September 24, 2020

The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.

FDA approval sought for novel PSMA imaging product in prostate cancer

September 24, 2020

A new drug application has been submitted to the FDA for TLX591-CDx, a radiopharmaceutical cold kit for the preparation of 68Ga-PSMA-11 injection for PET imaging in prostate cancer.

Novel BiTE immuno-oncology therapy appears safe with preliminary efficacy in mCRPC

September 21, 2020

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Olaparib significantly improves OS in mCRPC subgroup

September 21, 2020

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.

New report adds insight on prostate MRI for monitoring during active surveillance

September 18, 2020

Based on the findings, investigators recommended that systematic biopsy be performed in patients with negative MRI and in addition to targeted biopsies in men with a positive MRI.

FDA grants fast track designation for oral mCRPC agent

September 16, 2020

The FDA has granted fast track designation to EPI-7386, an oral, highly selective N-terminal domain inhibitor of the androgen receptor for treatment of mCRPC resistant to standard-of-care treatment.

Darolutamide survival benefit in prostate cancer highlighted in NEJM

September 11, 2020

Updated results were also reported on other key end points, including time to pain progression, first symptomatic skeletal event, and initiation of chemotherapy.

Nivolumab/ipilimumab dual immune-checkpoint blockade active in mCRPC

September 10, 2020

Combination approach could overcome mechanisms that previously led to poor outcomes with single-agent checkpoint inhibition.

Options increase for next-generation prostate cancer imaging

September 10, 2020

Advances in receptor targeted PET imaging continue to refine the identification of metastatic disease.

PSA screening in prostate cancer: The controversy continues

September 09, 2020

A new analysis supports return to widespread screening.

HIFU allows 91% of patients to avoid radical prostate cancer treatment for 2 years

September 08, 2020

The results suggest the minimally-invasive procedure is an acceptable alternative to immediate surgery or radiation.

Why is rucaparib response higher in BRCA2- versus BRCA1-mutated prostate cancer?

September 02, 2020

Mark C. Markowski, MD, PhD, and Emmanuel S. Antonarakis, MD, provide potential explanations for the increased clinical activity of PARP inhibitors in BRCA2- versus BRCA1-mutated prostate cancer.

Active surveillance for prostate cancer can be individualized based on risk parameters

September 02, 2020

Personalized approach would reduce the number of biopsies some patients need to receive.

Analysis underscores cardiotoxicity risks with androgen signaling inhibitors in CRPC

September 01, 2020

The overall risk of cardiac disorders was higher with abiraterone versus enzalutamide.

Novel regimen shows potential in mCRPC with androgen signaling inhibitor resistance

August 28, 2020

Treatment with the pan-BET bromodomain inhibitor ZEN-3694 plus enzalutamide may re-sensitize patients to androgen receptor–targeting agents.

Similar outcomes observed with immediate vs delayed radical prostatectomy

August 28, 2020

Survival outcomes are not compromised in men undergoing active surveillance, a recent study finds.

FDA approves liquid biopsy as companion diagnostic for rucaparib in prostate cancer

August 27, 2020

The FoundationOne Liquid CDx pan-tumor liquid biopsy examines over 300 cancer-related genes in a patient’s blood sample to inspect for deleterious alterations.

Speaking of Urology: How to get started with HIFU for prostate cancer

August 24, 2020

In this episode, Samuel J. Peretsman, MD, discusses how to get started with HIFU for prostate cancer and performing robotic prostatectomy following HIFU.

Study shows HIFU safe, effective ablation option in prostate cancer

August 20, 2020

Focal therapy using HIFU may be offered as an alternative to the existing modalities of treatment for select patients with all risk profiles of prostate cancer.